Form 4: Acrivon Therapeutics Executive Acquires Shares

Katharine Peterson, Chief Accounting Officer at Acrivon Therapeutics, acquired 14,227 shares of common stock through restricted stock units.

Summary

• Katharine Peterson, Chief Accounting Officer at Acrivon Therapeutics, Inc., acquired 14,227 shares of common stock on May 18, 2026.
• These shares were acquired through restricted stock units (RSUs).
• The acquisition resulted in Peterson beneficially owning 18,134 shares of common stock following the transaction.
• The RSUs vest partially on November 18, 2026, with the remainder vesting in subsequent quarterly installments, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard executive compensation and retention mechanism rather than a significant new investment or divestment.

Positives

• Acquisition of 14,227 shares by a key executive indicates confidence in the company's future.
• The executive's beneficial ownership has increased to 18,134 shares.

Future Outlook

The vesting schedule for the restricted stock units indicates a future increase in the executive's equity stake, contingent on continued employment.

Industry Context

StockSavvy.ai notes that executive stock acquisitions, particularly through RSUs, are common in the biotechnology sector as a method of aligning executive interests with shareholder value and retaining talent.

Stakeholder Impact

• Shareholders: The acquisition by an executive can be seen as a positive signal of commitment, though the shares are issued as compensation.
• Employees: The vesting schedule reinforces the importance of continued service for equity realization.
• Management: Demonstrates standard executive compensation practices.

Next Steps

• Continued service by Katharine Peterson through the vesting dates of November 18, 2026, and subsequent quarterly installments.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Stock Acquisition, Restricted Stock Units, Executive Compensation, Beneficial Ownership